← Amylyx Pharmaceuticals, Inc. (AMLX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Amylyx Pharmaceuticals, Inc. (AMLX)
Pharmaceutical Preparations · market cap $3.5B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Amylyx Pharmaceuticals (AMLX) is a Cambridge-based biopharmaceutical company best known for AMX0035, which received U.S. approval as Relyvrio for ALS in September 2022 but was voluntarily withdrawn from the market in April 2024 after a confirmatory Phase 3 trial failed to demonstrate efficacy. The company retains $229M in cash (~18.6 months runway) and is pursuing AMX0035 in a separate Phase 3 indication and avexitide in Phase 3 for post-bariatric hypoglycemia (PBH), while carrying zero current product revenue.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AMX0035 | Phase 3 | Amyotrophic Lateral Sclerosis |
| Avexitide | Phase 3 | Post Bariatric Hypoglycemia |
Price & technical context
3-month
+53.7%
6-month
+95.7%
12-month
+106.6%
52-wk range
$11.38–$39.66
vs 50-day MA
-3.6%
vs 200-day MA
+52.3%
Realized vol
77.1%
Max drawdown
-57.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AMLX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.